Abstracts tagged "pregnancy"

Abstract Number: 1345 • ACR Convergence 2023
Maternal and Infant Outcomes Following Abatacept Exposure During Pregnancy
Michelle Ann Caesar, Diana Johnson, Kenneth Lyons Jones and Christina Chambers, University of California San Diego, La Jolla, CA
Background/Purpose: Abatacept is approved for the treatment of moderate to severe rheumatoid arthritis (RA) and psoriatic arthritis. However, there are limited data on the safety…
Abstract Number: 1683 • ACR Convergence 2023
Moving the ACR’s Reproductive Health Guidelines into Practice: Assessment of a Novel Reproductive Rheumatology ECHO
Megan Clowse¹, Teresa Swezey², Jerome (Jeff) Federspiel², Catherine Sims², Amanda Snyderman², Amy Corneli², Sarahn Wheeler² and JoAnn Zell³, ¹Duke University, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC, ³University of Colorado Anschutz Medical Campus, Denver, CO
Background/Purpose: Project ECHO™ in an education model that links experts with community providers through a series of video teleconferences. Each conference involves a brief didactic…
Abstract Number: 0468 • ACR Convergence 2023
Patients with Autoimmune Skin Diseases Are at Increased Risk of Adverse Pregnancy Outcomes
Heejo Keum¹, Bonnie Bermas², Shivani Patel¹, Benjamin Chong¹ and Heidi Jacobe¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Increased rates of adverse pregnancy outcomes (APOs) have been reported in association with rheumatologic diseases such as systemic lupus erythematosus (SLE), dermatomyositis (DM), and…
Abstract Number: 1347 • ACR Convergence 2023
Continuing Biologic DMARDs During Pregnancy in Women with Rheumatic Disease Was Not Associated with Increased Unfavorable Pregnancy Outcomes, Serious Infections, and Adverse Effects of Vaccination
Hiromi Shimada¹, Risa Wakiya², Shusaku Nakashima², Taichi Miyagi³, Yusuke Ushio⁴, Koichi Sugihara⁵, Rina Mino⁶, Mao Mizusaki², Kanako Chujo⁷, Ryoko Kagawa⁴, Hayamasa Yamaguchi⁴, Tomohiro Kameda² and Hiroaki Dobashi², ¹Kagawa University, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Miki-cho, Kita-gun, Japan, ⁶Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁷Kagawa University, Miki, Kita District, Kagawa, Japan
Background/Purpose: It is important to control disease activity during pregnancy in women with rheumatic diseases because its exacerbation is associated with increased adverse pregnancy outcomes.…
Abstract Number: 1684 • ACR Convergence 2023
The Impact of Pregnancy Timing on Outcomes in SLE
Catherine Sims¹, Amanda Eudy², Ceshae Harding¹, Cuoghi Edens³, Mehret Birru Talabi⁴, Rosalind Ramsey-Goldman⁵, Laura Neil¹ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³University of Chicago, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Northwestern University, Chicago, IL, ⁶Duke University, Chapel Hill, NC
Background/Purpose: To minimize risk of poor pregnancy outcomes, the ACR Reproductive Health Guideline recommends women conceive when SLE is well controlled and treated with pregnancy-compatible…
Abstract Number: 0469 • ACR Convergence 2023
Hydroxychloroquine and Preeclampsia Risk in Lupus Pregnancy: Results from a Large Regional Integrated Health Network
Julia Simard¹, Emily Liu², Amadeia Rector³, Miranda Cantu⁴, Daniel Kuo⁵, Eliza Chakravarty⁶, Maurice Druzin⁷, Gary Shaw⁷, Michael Weisman⁸ and Monique Hedderson², ¹Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ²Kaiser Permanente Division of Research, Oakland, CA, ³Stanford University, San Francisco, CA, ⁴Global Lupus Support Group, Portage, MI, ⁵Kaiser Permanente, Redwood City, CA, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Stanford University, Stanford, CA, ⁸Stanford, Los Angeles, CA
Background/Purpose: Pregnancies in patients with systemic lupus erythematosus (SLE) are at greater risk of preeclampsia. Hydroxychloroquine (HCQ) is recommended during SLE pregnancy to control disease…
Abstract Number: 1348 • ACR Convergence 2023
Reproductive Outcomes for Women with Vasculitis
Catherine Sims¹, Christine Yeung², Heather Tam³, Joyce Kullman⁴, Amanda Eudy⁵, Renee Borchin⁶, Cristina Burroughs⁶, Megan Clowse⁷ and Peter Merkel², ¹Duke University School of Medicine, Durham, NC, ²University of Pennsylvania, Philadelphia, PA, ³Vasculitis Patient Powered Research Network, Stanford, CA, ⁴Vasculitis Foundation, Kansas City, MO, ⁵Duke University, Raleigh, NC, ⁶University of South Florida, Tampa, FL, ⁷Duke University, Chapel Hill, NC
Background/Purpose: There are limited data on the reproductive health of women with vasculitis. This study utilized a large, prospective, international vasculitis pregnancy registry to survey…
Abstract Number: 1824 • ACR Convergence 2023
Breakthrough COVID-19 and Severity After Vaccination Among Pregnant Persons with Rheumatic Diseases
Anna Sutton¹, Carolyn Hilliard², Qiuyuan Qin³, Alfred Jared Anzalone⁴, Mary Toth⁵, Rena Patel⁶ and Namrata Singh⁷, ¹Department of Epidemiology, University of Washington School of Public Health, Woodinville, WA, ²Department of Internal Medicine SSM Saint Louis University, St. Louis, MO, ³Department of Public Health, University of Rochester, Rochester, NY, ⁴Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, ⁵Nemours Foundation, Orlando, FL, ⁶Departments of Medicine and Global Health, University of Washington, Seattle, WA, ⁷University of Washington, Bellevue, WA
Background/Purpose: Acknowledgment: Contributed on behalf of the National COVID Cohort Collaborative (N3C) ConsortiumIndividuals with rheumatologic diseases (RD) are at higher risk for severe COVID-19 compared…
Abstract Number: 0473 • ACR Convergence 2023
The Number of Rheumatoid Arthritis Patients Who Give up Pregnancy Due to the Disease Is Decreasing
Ryo Inoue¹, Sakiko Isojima¹, Toshihiro Matsui², Shigeto Tohma³ and Nobuyuki Yajima⁴, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa City, Tokyo, Japan, ²NHO Sagamihara National Hospital, Kanagawa, Japan, ³NHO Tokyo National Hospital, Dallas, TX, ⁴Showa-Universtiy of Medicine, Tokyo, Japan
Background/Purpose: Biologics have been shown not to be a disruption in pregnancy, and the reproductive health care environment surrounding rheumatoid arthritis patients has improved significantly.…
Abstract Number: 1349 • ACR Convergence 2023
Paternal Effects of Anti-TNFs in Inflammatory Arthritis
Zeynep Toker Dincer, Bahaddin Ates, Ayten Dag, Ilayda Turkoglu, Ali Yagiz Ayla and Serdal Ugurlu, Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and…
Abstract Number: 1968 • ACR Convergence 2023
Pregnancy Outcomes in Idiopathic Inflammatory Myopathies: A Comparison to the General American Population
Ana Valle¹, Melissa Fazzari² and Shereen Mahmood³, ¹Montefiore Medical Center, Bronx, NY, ²Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare autoimmune conditions which cause multi-organ inflammation, particularly in the skin, lungs, and muscles. It is known that many…
Abstract Number: 0474 • ACR Convergence 2023
Acute Cardiovascular Events During Pregnancy and Delivery in Patients with Autoimmune Rheumatic Diseases (ARDs): An Analysis of National Inpatient Sample
Karun Shrestha¹, Prakriti Subedi¹, Manoj Ghimire¹, Sajana Poudel², Kalpana Ghimire¹, Sai Keerthi Parvatheneni¹, Mrunalini Dandamudi¹, Laura Pedraza¹, Luisa Brito¹ and Liliya Gandrabur³, ¹Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY, ²Department of Internal Medicine, John H Stroger Jr Hospital of Cook County, Chicago, IL, ³SBH Health System, Forest Hills, NY
Background/Purpose: Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) & vasculitis are autoimmune rheumatic diseases (ARDs) with systemic involvement. Management of women with ARDs during pregnancy…
Abstract Number: 1350 • ACR Convergence 2023
Identification of ACR Guidelines for SLE Pregnancy Care in the Electronic Health Record
Noah Forrest¹, Joshua Waytz², April Barnado³, Megan Clowse⁴, Theresa Walunas¹ and Rosalind Ramsey-Goldman⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern Medicine, Chicago, IL, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Duke University, Chapel Hill, NC, ⁵Northwestern University, Chicago, IL
Background/Purpose: SLE is an autoimmune disease with an increased risk for poor outcomes in pregnancy. In 2020, ACR specified several recommendations to assist clinicians in…
Abstract Number: 2278 • ACR Convergence 2023
Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry
Cristiana Sieiro Santos¹, Paula Pérez García², Jose Ordas Martínez², Clara Moriano², Carolina Álvarez Castro² and Elvira Díez Álvarez², ¹Complejo Asistencial Universitario de León, León, Spain, ²CAULE, León, Spain
Background/Purpose: Pregnancy in patients with connective tissue diseases are known to be at high risk for the occurrence of adverse pregnancy outcomes. We aim toevaluate…
Abstract Number: 0475 • ACR Convergence 2023
Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States
Sabahat Usmani¹, Catherine Lavallee², Maria Antonelli³ and Cuoghi Edens⁴, ¹Weiss Memorial Hospital, Chicago, IL, ²Virginia Tech Carilion School of Medicine, Roanoke, VA, ³MetroHealth System, Cleveland, OH, ⁴University of Chicago, Chicago, IL
Background/Purpose: Endometriosis (ENDO) and Polycystic Ovarian Syndrome (PCOS) are underdiagnosed, often debilitating conditions with unknown etiologies that, like rheumatic diseases, affect reproductive-aged women. Recent studies…

« Previous Page
1
…
8
9
10
11
12
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].